NAD+ Boosting Compounds in Human Studies

Man reading a printed sheet while seated in an infusion recliner with an IV line in his arm

This page compares two NAD+ boosters studied in people, NR and NMN, and sets a supplement against an infusion visit. It reads what the studies say and where they stop.

What two human studies report

The National Library of Medicine hosts a study whose conclusion reads: NR is well‐tolerated in older adults with MCI and may enhance perfusion of the hippocampus regardless of underlying AD pathology.

The National Library of Medicine also hosts a second study on a different compound. It states that overall, these findings suggest the potential of NMN to improve physical performance in older adults.

Both findings use careful words. "May enhance" and "suggest the potential" are not promises.

Compounds versus infusions

A reader comparing a supplement with an infusion is comparing two different commitments. An infusion adds a visit each time. Healthline’s NAD+ Infusions: A Guide to Safety is the place to read about the drip route.

What the studies leave open

A finding about tolerance or physical performance does not give you a price. It does not say how long a benefit lasts or how often a dose repeats.

Ask any provider for both answers before you pay for a package. If they cite a study, ask which compound it tested and in whom.

Which reader each option fits

The studies above involve older adults. A younger reader should not assume the same result. A reader who wants the broader science behind drips can start with To IV or Not to IV: The Science Behind Intravenous Vitamin Therapy.

Our wider overview sits at NAD+ Supplements Benefits and Risks Overview.